A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Clinical trial NCT02358031 · COMPLETED

Trial details

NCT number: NCT02358031
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Recurrent Head and Neck Cancer Metastatic Head and Neck Cancer

Start date: 2015-03-19
Primary completion: 2019-02-25
Enrollment: 882

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.